PRESS RELEASE published on 02/22/2024 at 14:01, 7 months 6 days ago Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert® Mainz Biomed partners with Praxisdienst to distribute ColoAlert®, an innovative at-home stool test for colorectal cancer detection. The collaboration aims to improve healthcare by enhancing early diagnosis ColoAlert Mainz Biomed Colorectal Cancer Praxisdienst Distribution Partnership
BRIEF published on 02/22/2024 at 14:01, 7 months 6 days ago Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert® ColoAlert Diagnostic Mainz Biomed Colorectal Cancer Praxisdienst
PRESS RELEASE published on 02/21/2024 at 14:01, 7 months 7 days ago Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy Mainz Biomed partners with TomaLab to expand ColoAlert® availability in Italy, enhancing colorectal cancer screening. Collaboration brings advanced DNA technology for early detection to Italian healthcare Italy Mainz Biomed Colorectal Cancer TomaLab ColoAlert®
BRIEF published on 02/21/2024 at 14:01, 7 months 7 days ago Mainz Biomed announces a strategic partnership in Italy for ColoAlert® Italy ColoAlert Mainz Biomed Colorectal Cancer Early Screening
PRESS RELEASE published on 02/06/2024 at 14:01, 7 months 22 days ago MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY Mainz Biomed N.V. (NASDAQ:MYNZ) has established the 'European Oncology Lab' (EOL), a physician-led laboratory for expanding service offering to privately insured patients in Germany. The lab will offer ColoAlert® as a laboratory medical service directly to physicians and patients, addressing the crucial requirement for invoicing private health insurance companies Germany Mainz Biomed N.V. European Oncology Lab ColoAlert Privately Insured Patients
PRESS RELEASE published on 11/09/2023 at 14:01, 10 months 19 days ago Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
PRESS RELEASE published on 11/07/2023 at 14:01, 10 months 21 days ago Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
PRESS RELEASE published on 10/31/2023 at 13:01, 10 months 28 days ago Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
PRESS RELEASE published on 10/26/2023 at 14:01, 11 months 2 days ago Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
PRESS RELEASE published on 10/18/2023 at 14:01, 11 months 10 days ago Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
Published on 09/28/2024 at 02:06, 20 hours 38 minutes ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 20 hours 44 minutes ago Quantum Biopharma Provides Corporate Update
Published on 09/28/2024 at 02:00, 20 hours 44 minutes ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 22 hours 34 minutes ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 8 hours 43 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 3 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 4 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 4 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 4 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 4 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 4 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024